噻托溴铵联合沙美特罗/氟替卡松对重度慢性阻塞性肺病的疗效分析

目的探讨噻托溴铵联合沙美特罗/氟替卡松对重度慢性阻塞性肺病的疗效。方法将我院收治的169例重度慢性阻塞性肺病患者分为实验组以及对照组。对照组采用噻托溴铵进行治疗,实验组患者采用噻托溴铵联合沙美特罗/氟替卡松进行治疗。对两组患者的肺功能、血气分析、呼吸困难评分、临床疗效以及不良反应等进行比较。结果治疗后实验组第1秒用力呼气容积（FEV1）、呼气峰流速、FEV1占预估计值百分比（%）、用力肺活量（FVC）等肺功能指标较对照组改善程度明显（P〈0.05）;血气分析结果较对照组亦改善明显（P〈0.05）。两组呼吸困难评分比较差异有统计学意义（P〈0.05）。实验组治疗有效率94.4%（84/89）]明显高于对照组76.3%（61/80）]（P〈0.05）。两组不良反应差异无统计学意义（P〉0.05）。结论对重度慢性阻塞性肺病患者采用噻托溴铵联合沙美特罗/氟替卡松进行治疗,可改善患者肺功能,提高患者血气分析指标,改善患者预后,提高患者生活水平。

Efficacy analysis of Tiotropium Bromide combined with Salmeterol/Fluticasone in severe chronic obstructive pulmonary disease

Objective To investigate the efficacy of Tiotropium Bromide combined with Salmeterol/Fluticasone to severe chronic obstructive pulmonary disease.Methods 169 cases in our hospital with severe chronic obstructive pulmonary disease patients were divided into experimental group and control group,the control group were treated with Tiotropium Bromide,the experimental group were treated with Tiotropium Bromide combined Salmeterol/Fluticasone.The lung function,blood gas analysis results,dyspnoea scores,clinical effects and adverse reactions of the two groups were compared.Results The blood gas analysis,FEV1,peak expiratory flow,FEV1 accounted for pre-estimate of the percentage(%),FVC in the experimental group compared with the control group,there were significant improvements(P < 0.05);blood gas analysis results of the experimental group were also improved better than the control group(P < 0.05);there were significant difference of dyspnoea scores between the two groups(P < 0.05);the effective rate 94.4%(84/89)] was significantly higher than the control group 76.3%(61/80)].There were no significant differences of adverse reactions between the two groups(P > 0.05).Conclusion The treatment of Tiotropium Bromide combined with Salmeterol/Fluticasone in severe chronic obstructive pulmonary disease can improve pulmonary function,improve patients’ blood gas analysis,improve patients’ prognosis and improve patients’ standard of living.